New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
06:39 EDTONTYOncothyreon's L-BLP25 did not meet primary endpoint in Phase 3 trial
Oncothyreon announced that the pivotal Phase 3 clinical trial of L-BLP25, formerly referred to as Stimuvax, known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer. The trial was conducted by Merck Serono, a division of Merck KGaA of Darmstadt, Germany, under a license agreement with Oncothyreon. Despite not meeting the primary endpoint, notable treatment effects were seen for L-BLP25 in certain subgroups. Further analyses are planned in the coming weeks to explore the potential benefit-risk profile of L-BLP25 in certain populations. Merck Serono will discuss these data with external experts and regulatory authorities over the coming months. More detailed results from the START trial will be submitted for publication in a peer reviewed journal and presentation at upcoming scientific meetings.
News For ONTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:50 EDTONTYOncothyreon raises $40M in common stock and preferred stock offerings
Subscribe for More Information
September 17, 2014
18:29 EDTONTYOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTONTYOncothyreon fiels to sell common stock and convertible preferred stock
Oncothyreon announced that it intends to offer and sell shares of its Common Stock and Series A Convertible Preferred Stock in separate but concurrent underwritten public offerings. The Series A Convertible Preferred Stock is non-voting and convertible into shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. Cowen and Company, LLC is acting as the sole book-running manager in the offerings.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use